Kura Oncology, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 10, 2026, reporting a nine-month net loss of $211.875 million and its first product revenue since inception.

Key Highlights

  • Net loss of $70.215 million for the three months ended September 30, 2026, compared to $74.116 million in the same period of 2025, according to the filing.
  • Product revenue of $13.922 million was recorded in Q3 2026, with $28.810 million for the nine months ended September 30, 2026, versus zero in both comparable 2025 periods.
  • Total revenue of $61.978 million for the nine months ended September 30, 2026, up from $50.146 million in the nine months ended September 30, 2025.
  • Total assets declined to $566.497 million as of September 30, 2026, from $738.363 million as of December 31, 2025, the filing disclosed.
  • Accumulated deficit reached $1.385963 billion as of September 30, 2026, compared to $1.174088 billion at December 31, 2025.
  • Total stockholders' equity fell to $17.960 million as of September 30, 2026, from $174.135 million at December 31, 2025.
  • 91,878,694 shares of common stock were outstanding as of November 6, 2026, the filing stated.

Kura Oncology's Q3 2026 Financial Results: Product Launch, Rising Losses, and Equity Decline

According to the filing, Kura Oncology (NASDAQ:KURA) reported total revenue of $22.839 million for the three months ended September 30, 2026, compared to $20.750 million for the same quarter in 2025. The increase was driven by $13.922 million in net product revenue in Q3 2026, a line item that did not exist in the prior-year period. Collaboration revenue fell to $8.917 million in Q3 2026 from $20.750 million in Q3 2025. For the nine-month period, collaboration revenue was $33.168 million versus $50.146 million a year earlier.

The filing disclosed total operating expenses of $97.497 million for Q3 2026, compared to $100.747 million in Q3 2025. Research and development expenses were $66.878 million for the quarter, while selling, general and administrative expenses were $30.248 million. For the nine months ended September 30, 2026, research and development expenses totaled $194.032 million and selling, general and administrative expenses totaled $93.553 million. The operating loss for the nine-month period was $226.483 million, compared to $217.363 million in the year-ago period.

The balance sheet showed cash and cash equivalents of $57.937 million and short-term investments of $434.159 million as of September 30, 2026, compared to $149.099 million and $518.141 million, respectively, at December 31, 2025. The filing also noted a loss on equity method investment of $30.586 million and an offsetting gain on deconsolidation of subsidiary of $30.586 million, both recorded in Q3 2026 and both zero in the comparable 2025 period. During Q3 2026, the company issued 2,564 thousand shares of common stock, raising net proceeds of $31.537 million, according to the stockholders' equity statement.

What Was Disclosed

Kura Oncology's 10-Q for the period ended September 30, 2026, disclosed a nine-month net loss of $211.875 million, the first nine-month period with product revenue at $28.810 million, and a significant reduction in total stockholders' equity to $17.960 million from $174.135 million at year-end 2025.